1. Á¤ÀÇ ¹× ¿ª»ç


T¼¼Æ÷¿Í ´ë½Ä¼¼Æ÷, ´ÜÇÙ±¸°¡ Áõ½ÄÇÏ°í ºñ±«»ç¼º À°¾ÆÁ¾À» Çü¼ºÇÏ¿© ¿©·¯ ±â°üÀ» ħ¹üÇÏ¿© Á¤»óÁ¶Á÷À» ÆÄ±«ÇÏ´Â Áúº´ÀÌ´Ù. °¡Àå ÈçÇÏ°Ô Ä§¹üÇÏ´Â ±â°üÀº Æó, ÇǺÎ, ¾È±¸, ¸²ÇÁÀý, °£ µîÀÌ¸ç ±Þ¼º, ¾Æ±Þ¼º °æ°ú¸¦ º¸À̱⵵ ÇÏÁö¸¸ ´ëºÎºÐÀº ¸¸¼ºÀûÀ¸·Î Áö¼ÓµÈ´Ù. ¾î´À ¿¬·ÉÃþÀ̳ª ¹ß»ýÇÒ ¼ö ÀÖÁö¸¸ 20-40´ë¿¡ °¡Àå ÈçÇÏ°í ¿©ÀÚ¿¡¼­ ¾à°£ ¹ßº´À²ÀÌ ³ô´Ù. ¿øÀÎÀ» ¸ð¸£´Â ÀÚ±â ȤÀº ºñÀÚ±â Ç׿ø¿¡ ÀÇÇØ T¼¼Æ÷°¡ Ȱ¼ºÈ­µÇ¾î ´ÜÇÙ±¸, ´ë½Ä¼¼Æ÷¸¦ Áõ½Ä½Ã۰í À°¾ÆÁ¾À» Çü¼ºÇÏ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù.


2. Áø´Ü ¹× À¯Çü

(1) Áø´Ü

ÀÓ»ó¾ç»ó°ú ¹æ»ç¼± ¼Ò°ß ±×¸®°í Á¶Á÷ °Ë»ç¸¦ Á¾ÇÕÇÏ¿© Áø´ÜÇÑ´Ù. ¾î¶² °Ë»çµµ ÇÑ °¡Áö °Ë»ç¸¸À¸·Î È®ÁøÇÒ ¼ö ¾ø´Ù. Á¶Á÷ °Ë»çµµ Áø´Ü¿¡ ¸Å¿ì Áß¿äÇÏÁö¸¸ ºñ±«»ç¼º À°¾ÆÁ¾ÀÌ ´Ù¸¥ Áúº´¿¡¼­µµ ³ª¿Ã ¼ö ÀÖÀ¸¹Ç·Î ÀÓ»ó¼Ò°ß ¹× ´Ù¸¥ °Ë»ç¿Í ÇÔ²² Áø´ÜÇÒ ¼ö ÀÖ°í glucocorticoid·Î Ä¡·áÇÑ´Ù. 50%¿¡¼­ ÀúÀý·Î ÁÁ¾ÆÁö¹Ç·Î ÀÓ»óÁõ»óÀÇ °æÁßÀ» Á¶»çÇØ °æÇÒ °æ¿ì 2-3°³¿ù °üÂûÇÒ ¼öµµ ÀÖ´Ù.

´ëºÎºÐ Áõ»óÀÌ ¾øÀ» ¶§ ¿ì¿¬È÷ ÈäºÎ¹æ»ç¼± ÃÔ¿µ¿¡¼­ ¹ß°ßµÇ´Â °æ¿ì°¡ ¸¹´Ù. ±Þ¼º ȤÀº ¾Æ±Þ¼ºÀº ¼ö ÁÖ°£ ¹ß¿­, ÇÇ·Î, ½Ä¿åºÎÁø, üÁß °¨¼Ò µîÀÇ Àü½ÅÀû Áõ»óÀÌ ÀÖ´Ù°¡ ±âħ, È£ÈíºÎÀü, °üÀýÅë µîÀ» È£¼ÒÇÏ°í ¸¸¼ºÀº ¼ö°³¿ù¿¡ °ÅÃÄ Àü½ÅÁõ»ó ¾øÀÌ ¼­¼­È÷ ¹ßº´Çϴµ¥ 70%ÀÌ»óÀÌ ¸¸¼ºÀÌ´Ù. ¸ðµç ±â°üÀ» ħ¹üÇÒ ¼ö ÀÖÀ¸³ª ȯÀÚµéÀÇ 90%°¡ °£Áú¼º ¼¶À¯È­ÀÇ Æóº´º¯À» º¸¿© ³ëÀÛ¼º È£Èí°ï¶õ, ¸¶¸¥±âħÀ» È£¼ÒÇÑ´Ù. ±× ¿Ü Èä°­ ³», ¸»ÃÊ ¸²ÇÁ¼±ºñ´ë¸¦ º¸À̰í ÇǺÎÀÇ °áÀý»ó È«¹Ý, ¾È±¸ÀÇ Æ÷µµ¸·¿°À» ÀÏÀ¸ÄÑ ½Ç¸íÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ´Ù.


3. Ư¼º ¹× ÁøÇà

¼ºº°¿¡ °ü°è¾øÀÌ ³ªÀ̳ª ÀÎÁ¾, Áö¿ª¿¡ °ü°è¾øÀÌ ¹ßº´ÇÒ ¼ö ÀÖÀ¸¸ç, ¾î´À ³ªÀÌ¿¡µµ »ý±æ ¼ö ÀÖÀ¸³ª 20-40´ë¿¡ ´ëºÎºÐ ÈçÇϸç, ºñÈí¿¬ÀÚ¿¡ ÈçÇÏ´Ù.


ÀÌ º´ÀÇ 1st manifestationÀº ħ¹ü Àå±â¿¡ mononuclear inflammatory cells(´ëºÎºÐ CD4+ TH1 lymphocyte & mononuclear phagocyte accumulation)ÀÌ Ä§ÂøÇÏ´Â °ÍÀÌ´Ù. ÀÌ·± ¿°Áõ°úÁ¤ ÈÄ¿¡ granuloma°¡ Çü¼ºµÇ°í, macrophage, epitheloid cells and multinucleated giant cells°¡ ÀÀÁýµÈ´Ù.

sarcoidosis¿¡¼­ÀÇ organ dysfunctionÀº Ä§ÂøµÈ ¿°Áõ¼¼Æ÷µéÀÌ Ä§¹üÁ¶Á÷ÀÇ architecture¸¦

ÆÄ±«ÇÏ¿© »ý±ä´Ù. ¸¸¾à Á¶Á÷ÀÇ ±â´É¿¡ ÇʼöÀûÀÎ ±¸Á¶¹°µéÀÌ Ä§¹üµÈ´Ù¸é ÀÓ»óÀûÀ¸·Î º´ÀÌ

³ªÅ¸³¯ °ÍÀÌ´Ù.

ºÎ°ËÀ» ÇÏ¸é ´ëºÎºÐÀÇ Àå±â°¡ ħ¹üµÇ¾î ÀÖÁö¸¸, ÀÓ»óÀûÀ¸·Î´Â ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Àå±â

(lung & eye)³ª X-ray, skin, hilar node¿Í °°ÀÌ ½±°Ô °üÂûÇÒ ¼ö ÀÖ´Â Àå±â¿¡¸¸ º´ÀÌ ±¹ÇѵȴÙ.

¿¹¸¦ µé¸é,Æó¿¡¼­ inflammatory cell & granuloma°¡ alveoli, bronchi, and blood vesselÀ» ÆÄ±«ÇÏ¿© Á¤»ó °¡½º±³È¯¿¡ ÇÊ¿äÇÑ °ø±â¿Í Ç÷¾×»çÀÌÀÇ °ü°è¸¦ º¯È­½ÃŲ´Ù.

¸¹Àº ÆóÁ¶Á÷ÀÌ Ä§¹üµÇ¸é, ȯÀڴ ȣÈí°ï¶õÀ» ´À³¢°Ô µÈ´Ù. ¹Ý¸é sarcoidosisȯÀÚ ´ëºÎºÐÀº

°£¿¡¼­ granulomatous mononuclear cell inflammationÀÌ ÀÖÁö¸¸ ÈçÈ÷ Áõ»óÀ̳ª ´Ù¸¥ Àå±â¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áß´ëÇÑ ±â´ÉÀû °áÇÔÀÌ ¾ø´Ù.

¸¸¼ºÇü¿¡¼­ mononuclear cell inflammationÀº ¼ö³â°£ Áö¼ÓµÈ´Ù. ¿°Áõ Á¤µµ°¡ ¿À·£ ±â°£ ÃæºÐÈ÷ ½ÉÇÏ´Ù¸é ħ¹ü Àå±âÀÇ derangement´Â extensive damage, fibrosis, permanent organ

function loss¸¦ ÃÊ·¡ÇÑ´Ù.

´Ù¾çÇÑ antigens or self-antigens¿¡ ´ëÇÑ °ú´ÙÇÑ ¼¼Æ÷¸é¿ªÀ¸·Î ÀÎÇÏ¿© active sarcoidosis°¡ ¹ß»ýÇÑ´Ù°í ¹Ï¾îÁö´Âµ¥ ÀÌ·¯ÇÑ Ç׿øÀº T lymphocyte¸¦ trigger & proliferation½ÃŲ´Ù.

±× °á°ú TH1 lymphocyte response´Â Áõ°¡ÇÏ°í ¸¹Àº activated TH1 lymphocyte°¡ ħ¹ü Àå±â¿¡ ÃàÀûµÈ´Ù.

TH1 lymphocyte´Â º´ÀÌ ÀÖ´Â Àå±â¿¡ ºü¸¥ ¼Óµµ·Î Áõ½ÄÇÏ¿© ÃàÀûµÇ´Âµ¥ ÀÌ·¯ÇÑ T cell

proliferationÀº T cell growth factorÀÎ IL-2ÀÇ spontaneous release¿¡ ÀÇÇØ À¯ÁöµÈ´Ù.

ħ¹ü Àå±â¿¡ TH1 cellsÀÌ IL-2¸¦ ºÐºñÇϰí Áõ°¡µÈ ¼Óµµ·Î Áõ½ÄÇÏ´Â ¹Ý¸é ´Ù¸¥ Àå±â¿¡¼­ÀÇ T cell(bloodµî)Àº °¡¸¸È÷ ÀÖ´Ù. Ç÷¾× ³» TH1 cellÀÇ ¼ö´Â Á¤»óÀ̰ųª ¾à°£ °¨¼ÒµÇ¾î ÀÖ´Ù.

ħ¹üÀå±âÀÇ CD4+/CD8+ ratio´Â Á¤»óÁ¶Á÷À̳ª Ç÷¾×ÀÇ 2:1¿¡ ºñÇÏ¿© 10:1Á¤µµ·Î ³ô´Ù.

IL-12°ú °°Àº cytokines°ú mediators´Â ħ¹ü Àå±â¿¡ blood monocytes¸¦ ¸ðÀ¸°í À̸¦ Ȱ¼ºÈ­ÇÏ¿© granuloma Çü¼º¿¡ building blockÀ» Á¦°øÇÑ´Ù.

cellular immunityÁõ°¡ ¿Ü¿¡µµ active sarcoidosis¿¡¼­´Â hyperglobulinemia°¡ ¶ÇÇÑ Æ¯Â¡ÀÌ´Ù.

IgM anti-T cell antibody»Ó¸¸ ¾Æ´Ï¶ó ´Ù¾çÇÑ infectious agents¿¡ ´ëÇÑ Ç×üÀÌ´Ù. ±×·¯³ª ÀÌ Ç×ü°¡ sarcoidosisº´Àο¡ °ü¿©ÇÑ´Ù´Â Áõ°Å´Â ¾ø´Ù.


¡ÚÀÓ»ó¹ßÇö 


ºñ·Ï Àü½ÅÀû ÁúȯÀÌÁö¸¸ Æó°¡ °ÅÀÇ Ç×»ó ħ¹üµÇ¹Ç·Î ´ëºÎºÐÀÇ È¯Àڴ ȣÈí±â Áõ»óÀ¸·Î

ÀǷڵȴÙ.

Àå±â¿Í »ó°ü¾øÀÌ ÀÓ»ó¹ßÇöÀº TH1 lymphocyte-mononuclear phagocyte granulomatous

inflammatory processÀÚü ¶Ç´Â ÀÌ °úÁ¤À¸·Î ÀÎÇÑ permanent damage·Î ÀÎÇÑ ÇÕº´Áõ°ú

»ó°üÀÖ´Ù. 75%°¡ 40¼¼ ÀÌÀü¿¡ ¹ß»ýÇÑ´Ù.

asymptomatic formÀº ÈçÈ÷ chest film°ú °°Àº routine examination¿¡ ÀÇÇØ ¹ß°ßµÈ´Ù.

¼ÒÀ§ acute or subacute sarcoidosis(20-40%)´Â ¼öÁÖ¿¡ °ÉÃÄ °©Àڱ⠹߻ýÇÑ´Ù. ÀÌ·¯ÇÑ

ȯÀÚ´Â fever, fatigue, amlaise, anorexia, or weight loss¿Í °°Àº Àü½ÅÁõ»óÀ» º¸ÀδÙ.

ÀÌ·± Áõ»óµéÀº ÈçÈ÷ °æÇÏÁö¸¸ ´ë·« 25%´Â ½ÉÇÏ´Ù.


¸¹Àº ȯÀÚµéÀÌ cough, dyspnea, vague retrosternal chest discomfort and/or polyarthritis¿Í °°Àº È£Èí±â Áõ»óÀ» º¸ÀδÙ. acute group¿¡¼­ 2°¡Áö syndromesÀ» º¼ ¼ö Àִµ¥ i) Lofgren's syndrome: erythema nodosum complex + bilateral hilar adenopathy + jount sx(ankle, wrist, elbowÀÇ arthritis)

ii) Heerfordt-Waldenstrom syndrome: fever, parotid enlargement, anterior uveitis, and facial nerve palsy

1) Lung

90%°¡ CXR»ó abnormal findings¸¦ º¸ÀδÙ.

ÀüüÀûÀ¸·Î ¡­50%°¡ permanent pulmonary abnormality¸¦ º¸À̰í 5-15%°¡ progressive

fibrosis¸¦ º¸ÀδÙ.

lung sarcoidosis´Â 1Â÷ÀûÀ¸·Î interstitial lung diseaseÀ̸ç ÀÌ´Â alveoli, small bronchi, and small blood vesselsÀÇ inflammatory processÀÌ´Ù. ÀÌ·± ȯÀÚ´Â ÀüÇüÀûÀ¸·Î dyspnea(ƯÈ÷ DOE), dry cough¸¦ º¸ÀδÙ. ¸¸¾à pulmonary lesionÀÌ ¿ì¼¼ÇÏ´Ù¸é À̸¦ necrotizing

sarcoidal granulomatosis¶ó ºÎ¸¥´Ù.

2) LN

lymphadenopathy°¡ ¾ÆÁÖ ÈçÇÏ´Ù. intrathoracic node´Â 75-90%¿¡¼­ Ä¿Áö¸ç ÈçÈ÷ hilar

node¸¦ ħ¹üÇÏÁö¸¸ paratracheal nodeµµ ÈçÈ÷ ħ¹üµÈ´Ù. peripheral lymphadenopathyµµ

¾ÆÁÖ ÈçÇÏ¸ç Æ¯È÷ cervical, axillary, epitrochlear, and inguinal node¿¡ ±×·¸´Ù. Àӯļ±µéÀº ¸ðµÎ nonadherentÀ̸ç firm, rubbery texture¸¦ º¸ÀδÙ. ¸¸Á³À» ¶§ ÅëÁõÀº ¾ø´Ù.

°áÇÙ¼º Àӯļ±°ú ´Þ¸® ±Ë¾çÀÌ Çü¼ºµÇÁö ¾Ê´Â´Ù.


¡Ú°Ë»ç½Ç ¼Ò°ß


Ç÷¾×°Ë»ç »ó ÈçÇÑ ÀÌ»óÀº lymphocytopeniaÀÌ¸ç °£È¤ mild eosinophilia°¡ º¸ÀÏ ¼ö ÀÖ´Ù.

ESRÀÌ Áõ°¡µÇ°í hypergammaglobulinemia, ACEÁõ°¡°¡ º¸ÀÏ ¼ö ÀÖ´Ù.

RF or ANA¿¡ ´ëÇÑ false-positive test°¡ ÀÖÀ» ¼ö ÀÖ´Ù. hypercalcemia´Â µå¹°´Ù.

Æó±â´ÉÀº ILDÀÇ ÀüÇüÀ̸ç lung volume & diffusing capacity´Â °¨¼ÒµÈ´Ù.

°£È¤ airflow limitationÀÌ ³ªÅ¸³ª±âµµ ÇÑ´Ù. º¸Åë mild hypoxemia & mild, compensated

hypocarbia¸¦ º¸ÀδÙ.

Ga-67 lung scanÀº º¸Åë ºñÁ¤»óÀ̸ç diffuse uptake patternÀ» º¸ÀδÙ. ¸¸¾à enlarged node °¡ Ga scan¿¡¼­ °üÂûµÈ´Ù¸é extrathoracic siteÀÇ ´Ù¾çÇÑ inflammationÀº ÀÓ»óÀû Á߿伺ÀÌ ¾ø´Ù.

BALÀº ÀüÇüÀûÀ¸·Î lymphocyte°¡ Áõ°¡µÇ¾î ÀÖÀ¸¸ç ´ëºÎºÐÀº activated TH1 cellÀÌ´Ù. ³ª¸ÓÁö cellÀÇ ´ëºÎºÐÀº alveolar macrophageÀÌ´Ù.

 


¡Ú¿¹ÈÄ 


ÀüüÀû ¿¹ÈÄ´Â ÁÁ´Ù. aucte disease·Î ¹ßÇöµÈ ´ëºÎºÐÀÇ È¯ÀÚ°¡ Áß´ëÇÑ ÇÕº´Áõ ¾øÀÌ È¸º¹

µÈ´Ù. ¸ðµç ȯÀÚ Áß ¾à ¹ÝÀÌ permanent organ dysfunctionÀ» º¸ÀÌÁö¸¸ ÀÌ ´ëºÎºÐÀº °æÇϰí, stable GÇϸç ÁøÇàÀº µå¹°´Ù. 15-20%´Â ¿©ÀüÈ÷ Ȱµ¿¼ºÀ¸·Î ³²¾Æ °£È¤ Àç¹ßÇÑ´Ù. »ç¸ÁÀº 0¡­10% ÀÌ´Ù.



4. ¿øÀÎ


¿øÀÎÀº ¾Ë·ÁÁöÁö ¾Ê°í ÀÖ´Ù.

´Ù¾çÇÑ infectious & noninfectious agent°¡ °ü·ÃµÇ³ª ƯÁ¤ÀÎÀÚ°¡ ¿øÀÎÀ̶ó´Â Áõ°Å´Â ¾ø´Ù.

±×·¯³ª ÀÌ º´ÀÌ cellular immune response(acquired, inherited, or both)¿¡ ÇÕ´çÇÏ´Ù.



5. Ä¡·á ¹× ±³À°

 

óġ¾àÀº glucocorticoidÀÌ´Ù. ´Ù¸¥ ¾àµéÀº È¿°ú°¡ ¾ø´Ù.

¾ÈÁõ»óÀÇ 75%´Â anterior uveitis·Î ³ªÅ¸³ª¸ç ´ëºÎºÐ ÀÚ¿¬ Ä¡·áµÈ´Ù.



6. Ãâó ¹× °ü·Ã »çÀÌÆ®

(1)Ãâó
http://www.kmle.co.kr/harrisonview.php?view=108+%C8%A3%C8%ED%B1%E2+%B3%BB%B0%FA+-+Sarcoidosis%28%BB%E7%B8%A3%C4%DA%C0%CC%B5%E5%C1%F5%29.htm


»ý¸í³ª´®°øµ¿Ã¼ http://blog.daum.net/hand727/9173751